Prosthetic Joint Infections Treatment Market

Global Prosthetic Joint Infections Treatment Market By Treatment (Antibiotics, Debridement, Irrigation with Implant Retention), By End-user (Hospitals, Clinics) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa)

  • Report ID: HC-46
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 12
  • No. Of Pages: 157
  • Format:
  • Pub. Date: 2020-07-23
  • Share:

Market Outlook:

The global prosthetic joint infections treatment market was valued at USD 95.59 Million in 2019 and is projected to reach USD 120.59 Million by 2027, expanding at a CAGR over 2.7% during the forecast period. Prosthetic implantations improve a patient’s quality of life; however, some related complications include aseptic failure and PJI infection. Infections caused by prosthetic joints require the combination of medical and surgical care. Treatments aim at alleviating suffering, restoring functions, and eliminating the infection. Factors need to be considered when selecting an appropriate approach for an individual patient are type of infection, presence of loosening, functional prognosis, etiology, and preferences of the patient. The market is driven by factors such as increasing incidence of road accidents and severe sports injuries and rising incidences of prosthetic joint infection (PJI). This, in turn, is boosting market growth.

Global Prosthetic Joint Infections Treatment Market Size

Manufacturers are focused on developing innovative drugs for the treatment of PJI and technological advancement and development of innovative treatment options for the treatment of the ailment, which in turn, is propelling the growth of the market. The integration between government reimbursement policies with hospitals & clinics and the launch of innovative products for the treatment of PJI are the key opportunities in this market. Factors restraining the growth of this market include high cost of PJI treatment and lack of trained pathologists for performing the histological analysis.

Market Dynamics
Rising Incidences of PJI
Prosthetic joint infection or PJI is a serious complication in joint replacement surgeries. It is a major threat in surgeries such as total joint arthroplasty (TJA), knee replacements surgery, and hip replacements surgery. Rise in number of knee replacements and hip replacement surgeries surges the risk of infections, which in turn, is expected to boost the market growth during the forecast period. According to the Orthobullets, Epidemiology of Prosthetic Joint Infection 2020, the incidence rate of infection for primary joint replacement surgeries for total hip arthroplasty (THA) is around 3% and for total knee arthroplasty (TKA) is around 2%. According to same source, the risk of injection for revision joint replacement surgeries is more than primary joint replacement surgeries, the reported risk of infection for THA is around 6%, while that of TKA is around 4%. These factors are projected to boost the prosthetic joints infection treatment market during the forecast period.

Growing Focus of Manufacturers on Developing Innovative Drugs for PJI
Increasing demand for the treatment of prosthetic joint infection has encouraged major players to invest more in research activities to develop new innovative products indicated for treating prosthetic joint infection. Manufacturers are engaged in clinical trials for drug compounds to treat PJI. A few players have succeeded in getting approval from regulatory bodies for clinical trial. For instance, Nabriva Therapeutics plc, has Lefamulin (IV/Oral) compound in Phase I of clinical trial for the indications including STIs, HABP/VABP, Osteomyelitis, and prosthetic joint infection.  Moreover, Arrevus have ARV 1801 in the Phase II clinical trial. Whereas, others players including Mellinta therapeutics and Telephus Medical have their compounds under pipeline for the prosthetic joint infection indication. This is expected to drive the market growth in the coming years.

Segmental Outlook

On the basis of treatments, the market has been divided into antibiotics, debridement, and irrigation with implant retention. The debridement segment is expected to hold at substantial market share during the forecast period as debridement consumes less time, is easier to perform than other surgeries, and requires reduced physiologic effects, hastening recovery. The antibiotics segment is anticipated to expand at a CAGR of around 3.6% during the forecast period, as new antibiotics in the market lead to successful outcomes with regards to function and quality of life.

Global Prosthetic Joint Infections Treatment Market BPS Analysis

Based on end-user, the market has been bifurcated into hospitals and clinics. The hospital segment is projected to constitute around 63.88% share of market in 2026 at CAGR of approximately 2.9%. The clinical segment is estimated to expand at substantial CAGR of over 2.4% during the forecast period.
 

Regional Outlook

On the basis of regions, the global penetrating market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). North America is a key region of the market. It accounted for market share of over 34.55% in 2019. Increase in the acceptance for novel treatments and technological advancements in the US, is expected to boost the demand for PJI treatment in the country during the forecast period. The market in Asia Pacific is estimated to expand at a significant CAGR of around 3.2% due to the increasing awareness regarding PJI treatment.

Global Prosthetic Joint Infections Treatment Market By Region

Competitive Landscape

  • Key players in the prosthetic joint infections treatment market include MELINTA THERAPEUTICS, INC., Nabriva Therapeutics plc, and Arrevus. They are considered as key manufacturers in the market based on their product availability, regional presence, supply chain management system, and increasing demand for their product. 
  • The players are adopting key strategies such as acquisition, and geographical expansion where potential opportunity for the Prosthetic Joint Infections Treatment extraction is added in the company’s capacity. 
  • For instance, In 2019, Arrevus finalized the acquasition of fusidic acid from Melinta Therapeutics. This enabled Arrevus to increase the treatment in joint infection. This fusidic acid is present in development phase of clinical trial.
  • On January 20, 2020, TenNor Therapeutics Ltd received FDA Orphan Drug Designation for TNP- 2092, which helps treat PJI. The company, recently, completed clinical phase II for TNP- 2092 for the treatment of ABSSSI.

Global Prosthetic Joint Infections Treatment Market By Manufacturers

Key Benefits for Industry Participants & Stakeholders

  • In-depth Analysis of the Global Prosthetic Joint Infections Treatment Market
  • Historical, Current and Projected Market Size in terms of Value
  • Potential & Niche Segments and Regions Exhibiting Promising Growth Covered 
  • Industry Drivers, Restraints and Opportunities Covered in the Study
  • Recent Industry Trends and Developments
  • Competitive Landscape & Strategies of Key Players
  • Neutral Perspective on Global Prosthetic Joint Infections Treatment Market Performance
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Prosthetic Joint Infections Treatment Market Overview

   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Prosthetic Joint Infections Treatment Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity

      4.2.4 Market Trends
   4.3 Prosthetic Joint Infections Treatment Market - Supply Chain Analysis
   4.4 By Type

      4.4.1 Fusidic Acid
      4.4.2 Lefamulin Acetate
      4.4.3 TNP-2092
      4.4.4 MTF-101
   4.5 Pipeline Analysis
   4.6 Future Perspective: Ambulatory Surgical Centers
   4.7 Revision Surgery Outlook

   4.8 Global Prosthetic Joint Infections Treatment Market Size & Forecast, 2017-2027
      4.8.1 Prosthetic Joint Infections Treatment Market Size and Y-o-Y Growth
      4.8.2 Prosthetic Joint Infections Treatment Market Absolute $ Opportunity

Chapter 5 Global Prosthetic Joint Infections Treatment Market Analysis and Forecast By Treatment
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Treatment
      5.1.2 Basis Point Share (BPS) Analysis By Treatment
      5.1.3 Absolute $ Opportunity Assessment By Treatment
   5.2 Prosthetic Joint Infections Treatment Market Size Forecast By Treatment
      5.2.1 Antibiotics
      5.2.2 Debridement
      5.2.3 Irrigation with Implant Retention
   5.3 Market Attractiveness Analysis By Treatment

Chapter 6 Global Prosthetic Joint Infections Treatment Market Analysis and Forecast By End-user
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By End-user
      6.1.2 Basis Point Share (BPS) Analysis By End-user
      6.1.3 Absolute $ Opportunity Assessment By End-user
   6.2 Prosthetic Joint Infections Treatment Market Size Forecast By End-user
      6.2.1 Hospitals
      6.2.2  Clinics
   6.3 Market Attractiveness Analysis By End-user

Chapter 7 Global Prosthetic Joint Infections Treatment Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Prosthetic Joint Infections Treatment Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact
   8.1 Introduction
   8.2 Current & Future Impact Analysis
   8.3 Economic Impact Analysis
   8.4 Government Policies
   8.5 Investment Scenario

Chapter 9 North America Prosthetic Joint Infections Treatment Analysis and Forecast
   9.1 Introduction
   9.2 North America Prosthetic Joint Infections Treatment Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Prosthetic Joint Infections Treatment Market Size Forecast By Treatment
      9.6.1 Antibiotics
      9.6.2 Debridement
      9.6.3 Irrigation with Implant Retention
   9.7 Basis Point Share (BPS) Analysis By Treatment
   9.8 Absolute $ Opportunity Assessment By Treatment
   9.9 Market Attractiveness Analysis By Treatment

   9.10 North America Prosthetic Joint Infections Treatment Market Size Forecast By End-user
      9.10.1 Hospitals
      9.10.2  Clinics
   9.11 Basis Point Share (BPS) Analysis By End-user
   9.12 Absolute $ Opportunity Assessment By End-user
   9.13 Market Attractiveness Analysis By End-user

Chapter 10 Europe Prosthetic Joint Infections Treatment Analysis and Forecast
   10.1 Introduction
   10.2 Europe Prosthetic Joint Infections Treatment Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Prosthetic Joint Infections Treatment Market Size Forecast By Treatment
      10.6.1 Antibiotics
      10.6.2 Debridement
      10.6.3 Irrigation with Implant Retention
   10.7 Basis Point Share (BPS) Analysis By Treatment
   10.8 Absolute $ Opportunity Assessment By Treatment
   10.9 Market Attractiveness Analysis By Treatment

   10.10 Europe Prosthetic Joint Infections Treatment Market Size Forecast By End-user
      10.10.1 Hospitals
      10.10.2  Clinics
   10.11 Basis Point Share (BPS) Analysis By End-user
   10.12 Absolute $ Opportunity Assessment By End-user
   10.13 Market Attractiveness Analysis By End-user

Chapter 11 Asia Pacific Prosthetic Joint Infections Treatment Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Prosthetic Joint Infections Treatment Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Prosthetic Joint Infections Treatment Market Size Forecast By Treatment
      11.6.1 Antibiotics
      11.6.2 Debridement
      11.6.3 Irrigation with Implant Retention
   11.7 Basis Point Share (BPS) Analysis By Treatment
   11.8 Absolute $ Opportunity Assessment By Treatment
   11.9 Market Attractiveness Analysis By Treatment

   11.10 Asia Pacific Prosthetic Joint Infections Treatment Market Size Forecast By End-user
      11.10.1 Hospitals
      11.10.2  Clinics
   11.11 Basis Point Share (BPS) Analysis By End-user
   11.12 Absolute $ Opportunity Assessment By End-user
   11.13 Market Attractiveness Analysis By End-user

Chapter 12 Latin America Prosthetic Joint Infections Treatment Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Prosthetic Joint Infections Treatment Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Prosthetic Joint Infections Treatment Market Size Forecast By Treatment
      12.6.1 Antibiotics
      12.6.2 Debridement
      12.6.3 Irrigation with Implant Retention
   12.7 Basis Point Share (BPS) Analysis By Treatment
   12.8 Absolute $ Opportunity Assessment By Treatment
   12.9 Market Attractiveness Analysis By Treatment

   12.10 Latin America Prosthetic Joint Infections Treatment Market Size Forecast By End-user
      12.10.1 Hospitals
      12.10.2  Clinics
   12.11 Basis Point Share (BPS) Analysis By End-user
   12.12 Absolute $ Opportunity Assessment By End-user
   12.13 Market Attractiveness Analysis By End-user

Chapter 13 Middle East & Africa (MEA) Prosthetic Joint Infections Treatment Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Prosthetic Joint Infections Treatment Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Prosthetic Joint Infections Treatment Market Size Forecast By Treatment
      13.6.1 Antibiotics
      13.6.2 Debridement
      13.6.3 Irrigation with Implant Retention
   13.7 Basis Point Share (BPS) Analysis By Treatment
   13.8 Absolute $ Opportunity Assessment By Treatment
   13.9 Market Attractiveness Analysis By Treatment

   13.10 Middle East & Africa (MEA) Prosthetic Joint Infections Treatment Market Size Forecast By End-user
      13.10.1 Hospitals
      13.10.2  Clinics
   13.11 Basis Point Share (BPS) Analysis By End-user
   13.12 Absolute $ Opportunity Assessment By End-user
   13.13 Market Attractiveness Analysis By End-user

Chapter 14 Competition Landscape
   14.1 Prosthetic Joint Infections Treatment Market: Competitive Dashboard
   14.2 Global Prosthetic Joint Infections Treatment Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      14.3.1 Arrevus

      14.3.2 MELINTA THERAPEUTICS, INC.
      14.3.3 Nabriva Therapeutics plc
      14.3.4 Peptilogics
      14.3.5 Telephus Medical LLC
      14.3.6 TenNor Therapeutics Ltd
Key Segments Covered
By Treatment
  • Antibiotics
  • Debridement
  • Irrigation with Implant Retention
By End-user
  • Hospitals
  • Clinics

By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Spain
    • Russia
    • Rest of the Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of MEA
Key Market Players Profiled in the Report
  • Arrevus
  • MELINTA THERAPEUTICS, INC.
  • Nabriva Therapeutics plc
  • Peptilogics
  • Telephus Medical LLC
  • TenNor Therapeutics Ltd

Buy Report

FAQ Section

Some frequently asked quetions about this report!

Additional company profiles can be provided on request.

Yes, the pipeline analysis is available on request.

Yes, the report gives the brief introduction of the types of prosthetic joint infections.

Yes, the report covers product specific information such as antibiotics, debridement, and irrigation with implant retention, etc.

According to this Growth Market Reports report, the market from Prosthetic Joint Infections Treatment is likely to register a CAGR over 2.7% during forecast period 2020-2027, with an anticipated valuation of USD 120.59 million by the end of the 2027.

In addition to market size (in USD Million) and Company Market Share (in % for base year 2019), other data such as Pipeline analysis, Future Perspective: Ambulatory Surgical Centers, and Revision Surgery Outlook. Additionally, the report also has SWOT analysis for companies.

The increasing incidences of road accidents and severe sports injuries, rising incidences of PJI, growing focus of manufacturers on developing innovative drugs for PJI, technological advancements and developments of new innovative treatment option for PJI treatment, increasing focus on brand protection are expected to drive the market growth during forecast period.

Hospitals and Clinics are the key end-user that are driving the prosthetic joint infections treatment market.

Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.

COVID-19 hampered the orthopedic industry. This, in turn, is restraining the prosthetic joint infection treatment market. According to the survey, the risk of taking care of family members suffering from the COVID is high.

The base year considered for the global Prosthetic Joint Infections Treatment market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.

Major Manufactures include, MELINTA THERAPEUTICS, INC., Nabriva Therapeutics plc, and Arrevus.